Table 10 Cost parameters: distant metastases (treatment)
Annual costs | Share of patients | Duration | ||
|---|---|---|---|---|
Advanced melanoma treatment: immuno-suppressant drugs | 108,192 € | 85% | 1 year | |
Dabrafenib + Trametinib | 114,411 € | 12% | Quelle: Dossier [81], price adjustment 2019/20 | |
Ipilimumab | 91,788 € | 23% | Dossier Ipilimumab, advanced melanoma [85] | |
Nivolumab | 78,460 € | 6% | Dossier Nivolumab [82] | |
Pembrolizumab | 130,858 € | 13% | Dossier Pembrolizumab, Advanced Melanoma [86] Assumption: 60% men, 40% women | |
Vemurafenib | 93,108 € | 1% | Dossier Cobimetinmib 2015, advanced melanoma [87]; Vemurafenib as comparator | |
Nivolumab + Ipilimumab | 139,958 € | 8% | Dossier Nivolumab+Ipilimumab, advanced melanoma [88] | |
Vemurafenib + Cobimetinib | 90,637 € | 3% | Dossier Vemurafenib+Cobimetinib, advanced melanoma [87] | |
Chemotherapy | 9194 € | 5% | unlimited | Dacarbazin treatment (used in dossier [89] as comparator for Nivolumab+Ipilimumab, mean of therapy frequencies (1 × 17, 5 × 17) |
Surgery | 3000 € | 20% | Assumption (standard inpatient flat rate per case in Germany) | |
Radiotherapy | 4776 € | 5% | 1 year | KBV statistic 2012, following [90], S, 9 |
“Best supportive care” | 17,531 € | 5% | unlimited | Schmidt/Lipp/Drechsler, ISPOR 2014, poster PCN86 [58] |
Frequency of immunosuppressant therapy: Gerbasi [40] Frequency of therapies in general: assumption following Maio et.al, [57] | ||||
2nd line treatment | 17,531 € | Best supportive care, see above [58] | ||